Drug intelligence / Profile preview

QLS1304

Development stage: Phase 2
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

QLS1304 is a novel, oral, and highly selective small molecule inhibitor targeting lysine acetyltransferase 6A (KAT6A) and lysine acetyltransferase 6B (KAT6B). Developed by Qilu Pharmaceutical, it is designed to suppress tumor growth by inhibiting histone H3 acetylation, estrogen receptor (ER) target gene expression, cell cycle progression, MYC signaling, and other key oncogenic pathways. The drug is currently in Phase I clinical trials for advanced malignant solid tumors and ER-positive/HER2-negative breast cancer. It has received FDA Fast Track designation for the treatment of ER+/HER2− breast cancer[1][5][7].

Brand names: QLS1304QLS-1304QLS 1304
Other names: QLS1304 TabletsQLS-1304 TabletsQLS 1304 TabletsQLS-1304QLS1304QLS 1304

Targets

KAT6A (Lysine acetyltransferase 6A)KAT6B (Histone acetyltransferase KAT6B)

Beyond the preview

Go deeper on QLS1304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS1304.

Explore the full profile